|
| ||||||||||||||||||||||||||||||||||||||||||||||||
PEDIATRICS Vol. 106 No. 2 August 2000, pp. 344-345
AMERICAN ACADEMY OF PEDIATRICS:
Use of Inhaled Nitric Oxide
| |
ABSTRACT |
|---|
|
|
|---|
Approval of inhaled nitric oxide by the US Food and Drug Administration for hypoxic respiratory failure of the term and near-term newborn provides an important new therapy for this serious condition. This statement addresses the conditions under which inhaled nitric oxide should be administered to the neonate with hypoxic respiratory failure.
Hypoxic respiratory failure in neonates born at or near
term may be caused by such conditions as primary persistent pulmonary hypertension, respiratory distress syndrome, aspiration syndromes, pneumonia or sepsis, and congenital diaphragmatic hernia. Conventional therapies, which have not been validated by randomized controlled trials, include administration of high concentrations of oxygen, hyperventilation, high-frequency ventilation, the induction of alkalosis, neuromuscular blockade, and sedation.1 Despite
aggressive conventional therapy, neonatal respiratory failure was
associated with a high rate of mortality before the development of
extracorporeal membrane oxygenation (ECMO).2,3 Survival
and short-term morbidity rates have been superior in term and near-term
infants ( Inhaled nitric oxide (iNO) is a selective pulmonary vasodilator for
which the mechanism of action involves guanylyl cyclase activation
leading to production of cyclic guanosine monophosphate and subsequent
smooth muscle relaxation.5-7 Although several studies
have suggested that iNO improves oxygenation,8-14 the US
Food and Drug Administration (FDA) evaluated 2 large randomized multicenter controlled trials of term and near-term neonates with hypoxic respiratory failure that demonstrated improved outcome with iNO
therapy. The Neonatal Inhaled Nitric Oxide Study Group trial documented
that iNO reduced the need for ECMO15 without increasing
neurodevelopmental, behavioral, or medical abnormalities at 2 years of
age.16 These results were strengthened by the Clinical
Inhaled Nitric Oxide Research Group trial, in which iNO reduced the
need for ECMO and the incidence of chronic lung disease.17
iNO was not effective for infants with congenital diaphragmatic hernia.18
The limited data to date on hypoxic preterm neonates suggest that
low-dose iNO improves oxygenation but does not improve
survival.14,19 Additional large randomized trials of iNO
in premature neonates are required because they may experience more
toxic effects than term and near-term infants.14,19,20
It is critical that infants with hypoxic respiratory failure in whom
conventional ventilator therapy fails or is predicted to fail be cared
for in institutions that have immediate availability of
personnel, including physicians, nurses, and respiratory therapists, who are qualified to use multiple modes of ventilation and rescue therapies. Radiologic and laboratory support required to manage the
broad range of needs of these infants is also essential.
iNO should be administered using FDA-approved devices
that are capable of administering iNO in constant concentration ranges in parts per million or less throughout the respiratory cycle. Infants
who receive iNO therapy should be monitored according to
institutionally derived protocols designed to avoid the potential toxic
effects associated with iNO administration. These effects include
methemoglobinemia (secondary to excess nitric oxide concentrations), direct pulmonary injury (attributable to excess levels of nitrogen dioxide), and ambient air contamination.
In the trials of iNO therapy reported to date, the indication for use
has been failure of ventilatory therapy. ECMO, a therapy of
proven efficacy, usually is initiated if iNO therapy fails. Therefore,
institutions that offer iNO therapy generally should have ECMO
capability; if a center lacks ECMO capability, it should work in
collaboration with an ECMO center to prospectively establish appropriate iNO failure criteria and mechanisms for the timely transfer
of infants to the collaborating ECMO center. The diversity of
geography, climate, and transport capabilities necessitates that the
"timely transfer" be dictated by the location-specific transport
limitations as well as the severity of the infant's illness. Because
hypoxic respiratory failure is often rapidly progressive and abrupt
discontinuation of iNO may lead to worsening oxygenation,21 the risk of delayed provision of ECMO must
be considered carefully when determining the appropriate time of
transfer.
Plans for the care and referral of these infants should incorporate the
following recommendations.
34 weeks' gestation) treated with ECMO compared with
conventional therapy4; however, questions remain about the
long-term safety of ECMO.
![]()
RECOMMENDATIONS
Top
Abstract
Recommendation
References
COMMITTEE ON FETUS AND NEWBORN, 1999-2000
James A. Lemons, MD, Chairperson
Lillian R. Blackmon, MD
William P. Kanto, Jr, MD
Hugh M. MacDonald, MD
Carol A. Miller, MD
Warren Rosenfeld, MD
Craig T. Shoemaker, MD
Jane E. Stewart, MD
Michael E. Speer, MD
LIAISON REPRESENTATIVES
Michael F. Greene, MD
American College of Obstetricians and Gynecologists
Patricia Johnson, RN, MS, NNP
American Nurses Association, Association of Women's Health,
Obstetric and Neonatal Nurses, National Association of Neonatal Nurses
Arne Ohlsson, MD
Canadian Paediatric Society
Solomon Iyasu, MBBS, MPH
Centers for Disease Control and Prevention
Linda L. Wright, MD
National Institutes of Health
SECTION LIAISONS
Richard Molteni, MD
Section on Perinatal Pediatrics
Jacob C. Langer, MD
Section on Surgery
STAFF
James Couto, MA
| |
FOOTNOTES |
|---|
The recommendations in this statement do not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.
| |
ABBREVIATIONS |
|---|
ECMO, extracorporeal membrane oxygenation; iNO, inhaled nitric oxide; FDA, US Food and Drug Administration.
| |
REFERENCES |
|---|
|
|
|---|
-
Walsh-Sukys MC,
Tyson JE,
Wright LL,
Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes.
Pediatrics
2000;
105:14-20
[Abstract/Free Full Text] -
Hageman JR,
Adams MA,
Gardner TH
Persistent pulmonary hypertension of the newborn. Trends in incidence, diagnosis and management.
Am J Dis Child.
1984;
138:592-595
[Abstract/Free Full Text] - John E, Roberts V, Burnard ED Persistent pulmonary hypertension of the newborn treated with hyperventilation: clinical features and outcome. Aust Paedriatr J. 1988; 24:357-361
- UK Collaborative ECMO Trial Group UK collaborative randomized trial of neonatal extracorporeal membrane oxygenation. Lancet 1996; 348:75-82 [CrossRef][Medline]
-
Ignarro IJ,
Buga GM,
Wood KS,
Byrns RE,
Chaudhuri G
Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide.
Proc Natl Acad Sci U S A.
1987;
84:9265-9269
[Abstract/Free Full Text] - Palmer RM, Ferrige AG, Moncada S Nitric oxide release accounts for the biologic activity of endothelium-derived relaxing factor. Nature. 1987; 327:524-526 [CrossRef][Medline]
-
Frostell C,
Fratacci MD,
Wain JC,
Jones R,
Zapol WM
Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction [published correction appears in Circulation. 1991;84:2212].
Circulation.
1991;
83:2038-2047
[Abstract/Free Full Text] -
Day RW,
Lynch JM,
White KS,
Ward RM
Acute response to inhaled nitric oxide in newborns in respiratory failure and pulmonary hypertension.
Pediatrics.
1996;
98:698-705
[Abstract/Free Full Text] - Barefield E, Karle VA, Phillips JB III, Carlo WA Inhaled nitric oxide in term infants with hypoxemic respiratory failure . J Pediatr. 1996; 129:279-286 [CrossRef][Medline]
-
Roberts JD Jr,
Fineman JR,
Morin FC III,
Inhaled nitric oxide and persistent pulmonary hypertension of the newborn.
N Engl J Med.
1997;
336:605-610
[Abstract/Free Full Text] - Kinsella JP, Truog WE, Walsh WF, Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. J Pediatr. 1997; 131:55-62 [CrossRef][Medline]
- Wessel DL, Adatia I, Van Marter LJ, et al. Improved oxygenation in a randomized trials of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics. 1997;100(5). Available at http://www.pediatrics.org/cgi/content/full/100/5/e7. Accessed May 3, 2000
-
Davidson D,
Barefield ES,
Kattwinkel J,
et al, and the INO/PPHN Study Group
Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study.
Pediatrics.
1998;
101:325-334
[Abstract/Free Full Text] - The Franco-Belgium Collaborative NO Trial Group Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomized controlled trial. Lancet. 1999; 354:1066-1071 [CrossRef][Medline]
-
Neonatal Inhaled Nitric Oxide Study Group (NINOS)
Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure.
N Engl J Med
1997;
336:597-604
[Abstract/Free Full Text] - Neonatal Inhaled Nitric Oxide Study Group Inhaled nitric oxide in term and near-term infants: neurodevelopmental follow-up of the Neonatal Inhaled Nitric Oxide Study Group (NINOS). J Pediatr 2000; 136:611-617 [CrossRef][Medline]
-
Clark RH,
Kueser TJ,
Walker MW,
Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn.
N Engl J Med
2000;
342:469-474
[Abstract/Free Full Text] -
Neonatal Inhaled Nitric Oxide Study Group (NINOS)
Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia.
Pediatrics
1997;
99:838-845
[Abstract/Free Full Text] - Kinsella JP, Walsh WF, Bose CL, Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomized controlled trial. Lancet. 1999; 354:1061-1065 [CrossRef][Medline]
- Van Meurs KP, Rhine WD, Asselin JM, Durand DJ Response of premature infants with severe respiratory failure to inhaled nitric oxide. Pediatr Pulmonol. 1997; 24:319-323 [CrossRef][Medline]
-
Davidson D,
Barefield ES,
Kattwinkel J,
Safety of withdrawing inhaled nitric oxide therapy in persistent pulmonary hypertension of the newborn.
Pediatrics.
1999;
104:231-236
[Abstract/Free Full Text]
Pediatrics (ISSN 0031 4005). Copyright ©2000 by the American Academy of Pediatrics
This article has been cited by other articles:
![]() |
T. D. Pawlik, N. F. M. Porta, R. H. Steinhorn, E. Ogata, and R.-A. O. deRegnier Medical and Financial Impact of a Neonatal Extracorporeal Membrane Oxygenation Referral Center in the Nitric Oxide Era Pediatrics, January 1, 2009; 123(1): e17 - e24. [Abstract] [Full Text] [PDF] |
||||
![]() |
K Khambekar, S Nichani, D K Luyt, G Peek, R K Firmin, D J Field, and H C Pandya Developmental outcome in newborn infants treated for acute respiratory failure with extracorporeal membrane oxygenation: present experience Arch. Dis. Child. Fetal Neonatal Ed., January 1, 2006; 91(1): F21 - F25. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. P. Van Meurs, L. L. Wright, R. A. Ehrenkranz, J. A. Lemons, M. B. Ball, W. K. Poole, R. Perritt, R. D. Higgins, W. Oh, M. L. Hudak, et al. Inhaled Nitric Oxide for Premature Infants with Severe Respiratory Failure N. Engl. J. Med., July 7, 2005; 353(1): 13 - 22. [Abstract] [Full Text] [PDF] |
||||
![]() |
Committee on Fetus and Newborn Levels of Neonatal Care Pediatrics, November 1, 2004; 114(5): 1341 - 1347. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||




